|Articles|July 20, 2016
Mitsubishi Tanabe Joins Certara’s Simcyp Consortium
Certara announces the addition of Mitsubishi Tanabe to its Simcyp Consortium as the group’s 34th biopharmaceutical company.
Advertisement
Certara announces the addition of Mitsubishi Tanabe to its Simcyp Consortium as the group’s 34th biopharmaceutical company. Mitsubishi Tanabe has also licensed its proprietary Simcyp Population-based Simulator, which enables companies to study drug activity in virtual patients.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5